Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Contraria Biotech

Request full access

Develops innovative, cost-effective therapeutic and prophylactic drugs to combat global health challenges like antibiotic resistance, emerging diseases, and pandemics

Siena, ItalyFounded 2017Biotech & Life Sciences

About Contraria Biotech

Achilles Vaccines operates in the biopharmaceutical sector, focusing on the early-stage development of vaccines and immunotherapeutics. The company leverages a versatile technology platform that utilizes bacteria to produce self-adjuvanting vesicles capable of delivering antigenic molecules. Achilles Vaccines serves clients in the healthcare and pharmaceutical industries, addressing critical needs such as malaria, COVID-19, and bacterial infections. The company employs advanced laboratory and digital technologies, including the NGVR method, to rapidly identify effective vaccine targets. Its business model revolves around research and development, supported by significant seed financing and partnerships, such as the EU Malaria Fund. Revenue is generated through the development and commercialization of biopharmaceutical products, including vaccines and immunotherapeutics.

Source: Dealroom company data

At a glance

Status
Operational
Employees
11
Open positions
None listed
Dealroom signal
33.9/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Oncology, Drug Development, Vaccines, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SEED✓Equity / VC Jun 2020 $12M $48M European Investment Bank · Bill & Melinda Gates Foundation · Toscana Life Sciences · Fondazione Monte dei Paschi di Siena —
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Contraria Biotech website traffic

Latest recorded traffic for Contraria Biotech is 220 monthly website visits, down 18.5% over the last three months. Contraria Biotech's team grew 0% over the past year.

Latest monthly visits220 3-month web change-18.5% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Contraria Biotech in the Siena ecosystem

Live from Dealroom

The Contraria Biotech office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed4 investors entered at this stage

  • European Investment Bank
  • Bill & Melinda Gates Foundation
  • Toscana Life Sciences
  • Fondazione Monte dei Paschi di Siena
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇮🇹 Italy · Siena HQ
Book a demo for the full country breakdown

See Contraria Biotech’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.